Bcr-Abl
Los inhibidores de Bcr-Abl son terapias dirigidas que inhiben la proteína de fusión Bcr-Abl, formada debido a la translocación del cromosoma Filadelfia y que es un impulsor de la leucemia mieloide crónica (LMC). Esta proteína también influye en la angiogénesis, contribuyendo a la progresión tumoral. Los inhibidores de Bcr-Abl son cruciales en el tratamiento de la LMC y se están explorando por su potencial para inhibir la angiogénesis en varios tipos de cáncer. En CymitQuimica, ofrecemos inhibidores de Bcr-Abl de alta calidad para apoyar su investigación en biología del cáncer, angiogénesis y terapias dirigidas.
Se han encontrado 102 productos de "Bcr-Abl"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Asciminib
CAS:<p>Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).</p>Fórmula:C20H18ClF2N5O3Pureza:98.82% - 99.70%Forma y color:SolidPeso molecular:449.84Imatinib
CAS:<p>Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit</p>Fórmula:C29H31N7OPureza:99.42% - 99.94%Forma y color:Off White PowderPeso molecular:493.6XL228
CAS:<p>XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).</p>Fórmula:C22H31N9OPureza:99.07%Forma y color:SolidPeso molecular:437.54Bafetinib
CAS:<p>Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.</p>Fórmula:C30H31F3N8OPureza:94.16% - 99.68%Forma y color:SolidPeso molecular:576.62GNF-5
CAS:<p>GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.</p>Fórmula:C20H17F3N4O3Pureza:98% - 99.94%Forma y color:SolidPeso molecular:418.37Flumatinib mesylate
CAS:<p>Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.</p>Fórmula:C30H33F3N8O4SPureza:99.82%Forma y color:SolidPeso molecular:658.69CZC-8004
CAS:<p>CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.</p>Fórmula:C17H16FN5Pureza:99.29%Forma y color:SolidPeso molecular:309.34Adaphostin
CAS:<p>Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.</p>Fórmula:C24H27NO4Pureza:98.29%Forma y color:SolidPeso molecular:393.48Nilotinib monohydrochloride monohydrate
CAS:<p>Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosine</p>Fórmula:C28H22F3N7O·HCl·H2OPureza:99.93%Forma y color:SolidPeso molecular:583.99AST 487
CAS:<p>AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.</p>Fórmula:C26H30F3N7O2Pureza:98.17% - 99.56%Forma y color:SolidPeso molecular:529.56PD173955
CAS:<p>PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and</p>Fórmula:C21H16Cl2N4OSPureza:98.52% - 98.99%Forma y color:SolidPeso molecular:443.35Bosutinib hydrate
CAS:<p>Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.</p>Fórmula:C26H31Cl2N5O4Pureza:99.87%Forma y color:SolidPeso molecular:548.46BCR-ABL-IN-7
CAS:<p>BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.</p>Fórmula:C19H16FN3O3SPureza:98.28%Forma y color:SolidPeso molecular:385.41BCR-ABL1-IN-1
CAS:<p>BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.</p>Fórmula:C18H12F3N3O2Forma y color:SolidPeso molecular:359.3Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Fórmula:C28H23ClF3N7O2Forma y color:SolidPeso molecular:581.98Antiproliferative agent-30
CAS:<p>Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against</p>Fórmula:C24H26N4O4Forma y color:SolidPeso molecular:434.49BCR-ABL-IN-6
CAS:<p>BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.</p>Fórmula:C27H22F3N5O2Forma y color:SolidPeso molecular:505.49c-ABL-IN-2
CAS:<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Fórmula:C21H20N4OForma y color:SolidPeso molecular:344.41AN-019
CAS:<p>AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.</p>Fórmula:C25H17F6N5OPureza:98.99%Forma y color:SolidPeso molecular:517.43CHMFL-ABL-053
CAS:<p>CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.</p>Fórmula:C28H26F3N7O2Forma y color:SolidPeso molecular:549.55
